Home›Stocks›BBIO

BBIO — structural market context

BridgeBio Pharma, Inc.

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Oct 22. Each line shows the earlier value, the later value and their dates.

Price

Close $68.12 (Oct 22) vs $67.74 (Oct 21): +0.56%.

Volume

1.01× its 20-session average (2.8M) on Oct 22.

Includes pre- and post-market trading.

Short interest

Short interest 19.7M shares (settlement Sep 30) vs 21.5M (Sep 15).

No new publication in this window. Latest: settlement Sep 30, published Oct 10.

Fails-to-deliver

Latest file (settlements Sep 15–Sep 30, published Oct 16): 1 day with fails, largest 5K shares on Sep 18.

Previous file (settlements Sep 1–Sep 14, published Sep 30): 6 days with fails, largest 50K shares on Sep 14.

No new publication in this window.

Analyst rating actions

None recorded in this window.

Insider filings (Form 4)

None recorded in this window.

BBIO events and their magnitude

Latest SEC filing in the event study

8-K 8.01 · Other events · filed 2026-10-13 · View on sec.gov ↗

…

Open the Event Study →

BBIO short interest & days to cover

SHARES SHORT
19.7M
% OF FLOAT
11.8%
DAYS TO COVER
5.8
CHANGE VS PRIOR
-8.7%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-09-30 (23d ago)

BBIO fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-09-18 · 35d5K$67.31
2026-09-14 · 39d50K$72.44
2026-09-11 · 42d105$72.5

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

BBIO insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 0 purchases · 9 sales

InsiderTypeSharesValueFiled
Kumar Neil · director, officer: Chief Executive OfficerSale (S)1K$89K2026-09-21
Kumar Neil · director, officer: Chief Executive OfficerSale (S)9K$602K2026-09-21
Kumar Neil · director, officer: Chief Executive OfficerSale (S)1K$100K2026-08-20
Kumar Neil · director, officer: Chief Executive OfficerSale (S)8K$679K2026-08-20
Kumar Neil · director, officer: Chief Executive OfficerSale (S)2K$152K2026-08-20

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

BBIO analyst ratings

FirmActionRatingPublished
Morgan Stanleyprice_target—2026-10-21
Piper SandlerholdOverweight2026-10-19
Piper Sandlerprice_target—2026-10-19
UBSprice_target—2026-10-15
Barclaysprice_target—2026-10-07

Rating actions as published by the firms, from public feeds. They are not graded here.

Frequently asked questions

What is BBIO's short interest?
As of the FINRA settlement date 2026-09-30, BBIO had 19.7M shares sold short — 11.8% of its float, with 5.8 days to cover at average volume. FINRA publishes this data roughly two weeks after each twice-monthly settlement, so it is inherently delayed. A short-interest figure describes an aggregate position; it does not predict what the stock will do.
Are insiders buying BBIO?
In the last 12 months of SEC Form 4 filings, BBIO recorded 0 insider purchases and 9 sales reported on Form 4 (transaction codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.
What do analysts say about BBIO?
The most recent action: Morgan Stanley price_target on 2026-10-21. Rating actions are shown as published by the firms; they are not graded here.
Is this page telling me to buy or sell BBIO?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerThe platform

More tickers starting with B

B · Barrick Mining CorporationBAM · Brookfield Asset Management LtBAND · Bandwidth Inc.BBNX · Beta Bionics, Inc.BE · Bloom Energy CorporationBEAM · Beam Therapeutics Inc.All B →

BBIO: the full history

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.